While DOGE dismay has hammered Tesla stock, SpaceX is still flying high with investors as the world’s most valuable private company. But economic realities and the physical limits of beaming internet connectivity from space could puncture the good vibes.
Successful research translation isn’t a matter of pushing more intellectual property into the market. The real catalyst for impact lies in building researchers’ commercial capability from the outset, says CSIRO’s executive manager of Innovation Programs.
With the help of a modern wolf’s genetic code, a Texas-based company says DNA from the extinct dire wolf is now back in living animals.
Cyberhaven, which just raised $100 million at a $1 billion valuation, offers AI tools designed to prevent employees from putting proprietary information into tools like ChatGPT.
For Visa and rival Mastercard, fighting the explosion of fraud attempts is both a big expense–and an opportunity for profit.
New York-based Jones just raised $10 million to expand its nicotine lozenge company in the stodgy, $3 billion smoking cessation market.
Seeing a gap in the market for a female-focused wine, TWE and Reese Witherspoon’s Hello Sunshine teamed up to introduce a new wine brand to US and Australian audiences. The red, white, and sparkling results are just as sunny as you might imagine.
The EV company’s sales are tanking in all major markets as its Chinese rivals are surging. But Tesla’s problems are just beginning.
Manna has raised $30 million to fund an ambitious expansion, taking on well-funded competitors like Amazon, Alphabet and unicorn Zipline. It could be first to scale a mass drone delivery operation.
Australia’s visionary eye-health company Opthea, which raised almost $1 billion to bring its eye injection to market, is fighting for survival today after the failure of its first Phase-3 trial.